By Kate Baggaley
LAS VEGAS—Specialty drugs continue to be the main category in the FDA’s pipeline for new approvals heading into mid-2023, according to a session at Asembia’s AXS23 Summit.
Ray Tancredi, RPh, MBA, the divisional vice president for specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, discussed potential blockbuster drugs that have been approved recently or are likely to be approved within the next several years, including treatments